Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Pleyer, L; Dohner, H; Dombret, H; Seymour, JF; Schuh, AC; Beach, CL; Swern, AS; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Spandl, SM; Zebisch, A; Pichler, A; Pfeilstocker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R INT J MOL SCI. 2017; 18(2): 415

Fracture Risk after Stopping Adjuvant Denosumab in Hormone Receptor Positive Breast Cancer Patients on Aromatase Inhibitor Therapy – an Analysis of 3,425 Postmenopausal Patients in the Phase III ABCSG-18 trial

Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Bergh, J; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF; Gnant, M J BONE MINER RES. 2018; 33: 55-55.

Elucidating the contribution of AID to the clonal evolution of chronic lymphocytic leukemia

Schubert, M; Zaborsky, N; Huemer, M; Hopner, JP; Gassner, FJ; Arzt, C; Greil, R; Geisberger, R ONCOL RES TREAT. 2018; 41: 169-169.

Subgroup analysis in elderly patients with metastatic pancreatic cancer: Preliminary results of Austrian real world data with nab-paclitaxel/gemcitabine

Prager, G; Gerger, A; Eisterer, W; Mlineritsch, B; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubman, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Woll, E; Neumann, H; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Grunberger, B; Ohler, L ONCOL RES TREAT. 2018; 41: 125-126.

Four versus two years of Rituximab maintenance (R-maintenance) following Bendamustine plus Rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)

Rummel, M; Buske, C; Hertenstein, B; Lerchenmuller, CA; Koenigsmann, M; Lange, E; Reeb, M; Kaiser, U; Balser, C; Behringer, D; Durig, J; Gaska, T; Maschmeyer, G; Schliesser, G; Burchardt, A; Barth, J; Kauff, F; Hinke, A; Greil, R ONCOL RES TREAT. 2018; 41: 251-251.

Screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer. AGMT Gastric-5

Woll, E; Regitnig, P; Winder, T; Thaler, J; Hockl, P; Eisterer, W; Ganzer, H; Wustner, A; Andel, J; Greil, R ONCOL RES TREAT. 2018; 41: 255-255.

The HIV continuum of care in Austria from 2010 to 2016: data and challenges

Leierer, G; van Sighem, A; Rieger, A; Schmied, B; Sarcletti, M; Ollinger, A; Haas, B; Egle, A; Rappold, M; Zangerle, R J INT AIDS SOC. 2018; 21:

Real-World multicenter Austrian analysis of the safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer

Steger, G; Petru, E; Haslbauer, F; Marth, C; Egle, D; Galid, A; Sliwa, T; Lang, A; Kuehr, T; Petzer, A; Ruckser, R; Greil, R; Mlineritsch, B; Singer, C; Seifert, M; Andel, J; Kwasny, W; Pichler, P; Tinchon, C; Bartsch, R EUR J CANCER. 2018; 92: S97-S97.

Exome sequencing of tumors from the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development

Egle, A; Gassner, FJ; Hopner, JP; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Zaborsky, N ONCOL RES TREAT. 2018; 41: 31-31.

Spatial heterogeneity in diffuse large B-cell lymphoma

Magnes, T; Melchardt, T; Thorner, A; Neureiter, D; Klieser, E; Greil, R; Egle, A ONCOL RES TREAT. 2018; 41: 243-244.